The effect of diminished osteogenic signals on reduced osteoporosis recovery in aged mice and the potential therapeutic use of adipose-derived stem cells

Hen Yu Liu, Jeng Fong Chiou, Alexander T H Wu, Ching Yu Tsai, Jyh Der Leu, Lai Lei Ting, Ming Fu Wang, Hsuan Yu Chen, Che Tong Lin, David F. Williams, Win Ping Deng

研究成果: 雜誌貢獻文章

30 引文 (Scopus)

摘要

Adipose-derived stem cells (ADSCs) have been shown to be pluoripotent and explored for their usage in tissue engineering. Previously, we have established a cell-based approach comprised of platelet-enriched plasma and osteo-progenitor cells for treating osteoporosis in an ovariectomized-senescence-accelerated mice (OVX-SAMP8) model. In the present study, we intend to explore the feasibility of using ADSCs as a cell-based therapeutic approach for treating osteoporosis, and to examine the effects of aging on the pluoripotency of ADSCs and the efficiency of bone formation both in vitro and in vivo. Flow cytometry was used to characterize ADSCs isolated from young and aged female SAMP8 mice and showed that the highly positive expression of surface markers such as CD44 and CD105 and negative for CD34 and CD45. Therefore, to compare the aging effects on the growth kinetics and differentiation potential of young and aged ADSCs, we found that there was a significant decline in both the proliferation rate (approximately 13.3%) and osteo-differentiation potential in aged ADSC. Subsequently, young and aged ADSCs were transplanted into the bone marrow of osteoporotic mice (OVX-SAMP8) to evaluate their bone formation ability. ADSC transplants were shown effective in restoring bone mineral density in the right/left knees, femurs and spine, 4 months post-transplantation; mice which received young ADSC transplants showed significantly higher bone regeneration(an average of 24.3% of improved BMD) over those received aged ADSCs. In conclusion, these findings showed that aging impedes osteoporosis-ameliorating potential of ADSC by diminishing osteogenic signal, and that ADSC could be used as a potential cell-based therapy for osteoporosis.
原文英語
頁(從 - 到)6105-6112
頁數8
期刊Biomaterials
33
發行號26
DOIs
出版狀態已發佈 - 九月 2012

指紋

Therapeutic Uses
Stem cells
Osteoporosis
Stem Cells
Recovery
Bone
Transplants
Aging of materials
Osteogenesis
Transplantation (surgical)
Flow cytometry
Growth kinetics
Bone Regeneration
Platelets
Tissue engineering
Tissue Engineering
Cell- and Tissue-Based Therapy
Minerals
Bone Density
Femur

ASJC Scopus subject areas

  • Biomaterials
  • Bioengineering
  • Ceramics and Composites
  • Mechanics of Materials
  • Biophysics

引用此文

The effect of diminished osteogenic signals on reduced osteoporosis recovery in aged mice and the potential therapeutic use of adipose-derived stem cells. / Liu, Hen Yu; Chiou, Jeng Fong; Wu, Alexander T H; Tsai, Ching Yu; Leu, Jyh Der; Ting, Lai Lei; Wang, Ming Fu; Chen, Hsuan Yu; Lin, Che Tong; Williams, David F.; Deng, Win Ping.

於: Biomaterials, 卷 33, 編號 26, 09.2012, p. 6105-6112.

研究成果: 雜誌貢獻文章

Liu, Hen Yu ; Chiou, Jeng Fong ; Wu, Alexander T H ; Tsai, Ching Yu ; Leu, Jyh Der ; Ting, Lai Lei ; Wang, Ming Fu ; Chen, Hsuan Yu ; Lin, Che Tong ; Williams, David F. ; Deng, Win Ping. / The effect of diminished osteogenic signals on reduced osteoporosis recovery in aged mice and the potential therapeutic use of adipose-derived stem cells. 於: Biomaterials. 2012 ; 卷 33, 編號 26. 頁 6105-6112.
@article{7b6c04f951e8425d9f35cb8b72293aaf,
title = "The effect of diminished osteogenic signals on reduced osteoporosis recovery in aged mice and the potential therapeutic use of adipose-derived stem cells",
abstract = "Adipose-derived stem cells (ADSCs) have been shown to be pluoripotent and explored for their usage in tissue engineering. Previously, we have established a cell-based approach comprised of platelet-enriched plasma and osteo-progenitor cells for treating osteoporosis in an ovariectomized-senescence-accelerated mice (OVX-SAMP8) model. In the present study, we intend to explore the feasibility of using ADSCs as a cell-based therapeutic approach for treating osteoporosis, and to examine the effects of aging on the pluoripotency of ADSCs and the efficiency of bone formation both in vitro and in vivo. Flow cytometry was used to characterize ADSCs isolated from young and aged female SAMP8 mice and showed that the highly positive expression of surface markers such as CD44 and CD105 and negative for CD34 and CD45. Therefore, to compare the aging effects on the growth kinetics and differentiation potential of young and aged ADSCs, we found that there was a significant decline in both the proliferation rate (approximately 13.3{\%}) and osteo-differentiation potential in aged ADSC. Subsequently, young and aged ADSCs were transplanted into the bone marrow of osteoporotic mice (OVX-SAMP8) to evaluate their bone formation ability. ADSC transplants were shown effective in restoring bone mineral density in the right/left knees, femurs and spine, 4 months post-transplantation; mice which received young ADSC transplants showed significantly higher bone regeneration(an average of 24.3{\%} of improved BMD) over those received aged ADSCs. In conclusion, these findings showed that aging impedes osteoporosis-ameliorating potential of ADSC by diminishing osteogenic signal, and that ADSC could be used as a potential cell-based therapy for osteoporosis.",
keywords = "Adipose-derived stem cells (ADSCs), Bone regeneration, Osteoporosis, Ovariectomized senescence accelerated mice (OVX-SAMP8), Young and aged",
author = "Liu, {Hen Yu} and Chiou, {Jeng Fong} and Wu, {Alexander T H} and Tsai, {Ching Yu} and Leu, {Jyh Der} and Ting, {Lai Lei} and Wang, {Ming Fu} and Chen, {Hsuan Yu} and Lin, {Che Tong} and Williams, {David F.} and Deng, {Win Ping}",
year = "2012",
month = "9",
doi = "10.1016/j.biomaterials.2012.05.024",
language = "English",
volume = "33",
pages = "6105--6112",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier Science Ltd",
number = "26",

}

TY - JOUR

T1 - The effect of diminished osteogenic signals on reduced osteoporosis recovery in aged mice and the potential therapeutic use of adipose-derived stem cells

AU - Liu, Hen Yu

AU - Chiou, Jeng Fong

AU - Wu, Alexander T H

AU - Tsai, Ching Yu

AU - Leu, Jyh Der

AU - Ting, Lai Lei

AU - Wang, Ming Fu

AU - Chen, Hsuan Yu

AU - Lin, Che Tong

AU - Williams, David F.

AU - Deng, Win Ping

PY - 2012/9

Y1 - 2012/9

N2 - Adipose-derived stem cells (ADSCs) have been shown to be pluoripotent and explored for their usage in tissue engineering. Previously, we have established a cell-based approach comprised of platelet-enriched plasma and osteo-progenitor cells for treating osteoporosis in an ovariectomized-senescence-accelerated mice (OVX-SAMP8) model. In the present study, we intend to explore the feasibility of using ADSCs as a cell-based therapeutic approach for treating osteoporosis, and to examine the effects of aging on the pluoripotency of ADSCs and the efficiency of bone formation both in vitro and in vivo. Flow cytometry was used to characterize ADSCs isolated from young and aged female SAMP8 mice and showed that the highly positive expression of surface markers such as CD44 and CD105 and negative for CD34 and CD45. Therefore, to compare the aging effects on the growth kinetics and differentiation potential of young and aged ADSCs, we found that there was a significant decline in both the proliferation rate (approximately 13.3%) and osteo-differentiation potential in aged ADSC. Subsequently, young and aged ADSCs were transplanted into the bone marrow of osteoporotic mice (OVX-SAMP8) to evaluate their bone formation ability. ADSC transplants were shown effective in restoring bone mineral density in the right/left knees, femurs and spine, 4 months post-transplantation; mice which received young ADSC transplants showed significantly higher bone regeneration(an average of 24.3% of improved BMD) over those received aged ADSCs. In conclusion, these findings showed that aging impedes osteoporosis-ameliorating potential of ADSC by diminishing osteogenic signal, and that ADSC could be used as a potential cell-based therapy for osteoporosis.

AB - Adipose-derived stem cells (ADSCs) have been shown to be pluoripotent and explored for their usage in tissue engineering. Previously, we have established a cell-based approach comprised of platelet-enriched plasma and osteo-progenitor cells for treating osteoporosis in an ovariectomized-senescence-accelerated mice (OVX-SAMP8) model. In the present study, we intend to explore the feasibility of using ADSCs as a cell-based therapeutic approach for treating osteoporosis, and to examine the effects of aging on the pluoripotency of ADSCs and the efficiency of bone formation both in vitro and in vivo. Flow cytometry was used to characterize ADSCs isolated from young and aged female SAMP8 mice and showed that the highly positive expression of surface markers such as CD44 and CD105 and negative for CD34 and CD45. Therefore, to compare the aging effects on the growth kinetics and differentiation potential of young and aged ADSCs, we found that there was a significant decline in both the proliferation rate (approximately 13.3%) and osteo-differentiation potential in aged ADSC. Subsequently, young and aged ADSCs were transplanted into the bone marrow of osteoporotic mice (OVX-SAMP8) to evaluate their bone formation ability. ADSC transplants were shown effective in restoring bone mineral density in the right/left knees, femurs and spine, 4 months post-transplantation; mice which received young ADSC transplants showed significantly higher bone regeneration(an average of 24.3% of improved BMD) over those received aged ADSCs. In conclusion, these findings showed that aging impedes osteoporosis-ameliorating potential of ADSC by diminishing osteogenic signal, and that ADSC could be used as a potential cell-based therapy for osteoporosis.

KW - Adipose-derived stem cells (ADSCs)

KW - Bone regeneration

KW - Osteoporosis

KW - Ovariectomized senescence accelerated mice (OVX-SAMP8)

KW - Young and aged

UR - http://www.scopus.com/inward/record.url?scp=84862896868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862896868&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2012.05.024

DO - 10.1016/j.biomaterials.2012.05.024

M3 - Article

C2 - 22698723

AN - SCOPUS:84862896868

VL - 33

SP - 6105

EP - 6112

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 26

ER -